$CUE
Cue Biopharma Inc

2022 Q1 Form 10-K Financial Statement

#000095017022003969 Filed on March 16, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021
Revenue $1.000M $8.254M $14.94M
YoY Change -35.61% 1619.66% 373.68%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.156M $4.647M $17.29M
YoY Change 21.89% 35.87% 18.85%
% of Gross Profit
Research & Development $10.08M $11.21M $41.35M
YoY Change 2.71% 44.33% 23.26%
% of Gross Profit
Depreciation & Amortization $220.0K $309.7K $909.1K
YoY Change 0.92% 19.1% 16.47%
% of Gross Profit
Operating Expenses $15.24M $16.15M $58.65M
YoY Change 8.29% 41.03% 21.7%
Operating Profit -$14.24M -$43.71M
YoY Change 13.74% -2.95%
Interest Expense $25.00K $3.900K $45.90K
YoY Change -90.11%
% of Operating Profit
Other Income/Expense, Net -$17.00K $45.90K
YoY Change -230.77% -90.11%
Pretax Income -$14.26M -$7.889M -$43.67M
YoY Change 13.95% -27.62% -2.05%
Income Tax $495.0K $495.0K
% Of Pretax Income
Net Earnings -$14.26M -$8.384M -$44.16M
YoY Change 13.99% -24.47% -1.39%
Net Earnings / Revenue -1425.5% -101.57% -295.56%
Basic Earnings Per Share -$0.44 -$1.41
Diluted Earnings Per Share -$436.8K -$262.4K -$1.412M
COMMON SHARES
Basic Shares Outstanding 33.01M 31.29M
Diluted Shares Outstanding 32.64M 31.29M

Balance Sheet

Concept 2022 Q1 2021 Q4 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $67.93M $64.37M $64.37M
YoY Change -7.33% -24.15% -24.15%
Cash & Equivalents $67.93M $64.37M $64.37M
Short-Term Investments $0.00 $0.00 $0.00
Other Short-Term Assets $7.095M $954.8K $954.8K
YoY Change 162.78% -20.43% -23.0%
Inventory
Prepaid Expenses
Receivables $925.0K $3.142M $3.143M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $75.95M $68.47M $68.47M
YoY Change -1.88% -21.78% -21.78%
LONG-TERM ASSETS
Property, Plant & Equipment $1.918M $2.112M $11.92M
YoY Change -31.16% 0.19% 34.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $137.0K $140.0K $3.011M
YoY Change -95.28% -65.15% -3.49%
Total Long-Term Assets $14.76M $14.93M $14.93M
YoY Change 30.59% 24.38% 24.44%
TOTAL ASSETS
Total Short-Term Assets $75.95M $68.47M $68.47M
Total Long-Term Assets $14.76M $14.93M $14.93M
Total Assets $90.70M $83.40M $83.40M
YoY Change 2.26% -16.21% -16.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.617M $2.591M $2.591M
YoY Change 4.68% 25.15% 25.15%
Accrued Expenses $3.406M $4.620M $7.290M
YoY Change -51.34% 65.76% 3.12%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.41M $12.79M $12.79M
YoY Change -31.26% -21.62% -21.64%
LONG-TERM LIABILITIES
Long-Term Debt $9.861M $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.759M $5.121M $5.121M
YoY Change 98.29% 19.1% 18.82%
Total Long-Term Liabilities $9.861M $0.00 $5.121M
YoY Change 310.88% -100.0% 18.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.41M $12.79M $12.79M
Total Long-Term Liabilities $9.861M $0.00 $5.121M
Total Liabilities $26.03M $17.91M $17.91M
YoY Change 36.29% -13.16% -13.15%
SHAREHOLDERS EQUITY
Retained Earnings -$211.7M -$197.4M
YoY Change 28.81%
Common Stock $276.4M $262.9M
YoY Change 13.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $64.67M $65.49M $65.49M
YoY Change
Total Liabilities & Shareholders Equity $90.70M $83.40M $83.40M
YoY Change 2.26% -16.21% -16.21%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021
OPERATING ACTIVITIES
Net Income -$14.26M -$8.384M -$44.16M
YoY Change 13.99% -24.47% -1.39%
Depreciation, Depletion And Amortization $220.0K $309.7K $909.1K
YoY Change 0.92% 19.1% 16.47%
Cash From Operating Activities -$11.57M -$10.65M -$38.84M
YoY Change -1.88% 52.29% 19.52%
INVESTING ACTIVITIES
Capital Expenditures $27.00K -$40.00 $913.0K
YoY Change -95.83% -99.96% 53.39%
Acquisitions
YoY Change
Other Investing Activities $0.00 $550.00 $10.02M
YoY Change -100.0% -99.99% 98.45%
Cash From Investing Activities -$27.00K $510.00 $9.109M
YoY Change -100.29% -99.99% 104.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $191.0K -$16.63M
YoY Change 124.71% -70.51%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 15.16M 7.382M 19.23M
YoY Change 1717.27% 2975.97% -67.19%
NET CHANGE
Cash From Operating Activities -11.57M -10.65M -38.84M
Cash From Investing Activities -27.00K 510.0 9.109M
Cash From Financing Activities 15.16M 7.382M 19.23M
Net Change In Cash 3.556M -3.262M -10.50M
YoY Change -321.01% -203.57% -134.33%
FREE CASH FLOW
Cash From Operating Activities -$11.57M -$10.65M -$38.84M
Capital Expenditures $27.00K -$40.00 $913.0K
Free Cash Flow -$11.60M -$10.65M -$39.75M
YoY Change -6.77% 54.73% 20.13%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001645460
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 cue Issuance Of Common Stock Upon Net Exercise Of Warrants Value
IssuanceOfCommonStockUponNetExerciseOfWarrantsValue
CY2021Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-38327
CY2021 dei Entity Registrant Name
EntityRegistrantName
Cue Biopharma, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3324577
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
21 Erie Street
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
CY2021 dei City Area Code
CityAreaCode
617
CY2021 dei Local Phone Number
LocalPhoneNumber
949-2680
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2021 dei Trading Symbol
TradingSymbol
CUE
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
362600000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
33010702
CY2021 dei Auditor Firm
AuditorFirmId
49
CY2021 dei Auditor Name
AuditorName
RSM US LLP
CY2021 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64370800
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74866133
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
10002550
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3142527
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1417482
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
954792
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1241239
CY2021Q4 us-gaap Assets Current
AssetsCurrent
68468119
CY2020Q4 us-gaap Assets Current
AssetsCurrent
87527404
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2111949
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2108024
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9809876
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6774229
CY2021Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2720991
CY2020Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2572476
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
150000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
150000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
140000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
401667
CY2021Q4 us-gaap Assets
Assets
83400935
CY2020Q4 us-gaap Assets
Assets
99533800
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2590701
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2070303
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4619963
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2787211
CY2021Q4 cue Research And Development Contract Liability Current
ResearchAndDevelopmentContractLiabilityCurrent
645345
CY2020Q4 cue Research And Development Contract Liability Current
ResearchAndDevelopmentContractLiabilityCurrent
6681025
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4931675
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4777427
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12787684
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16315966
CY2021Q4 cue Research And Development Contract Liability Noncurrent
ResearchAndDevelopmentContractLiabilityNoncurrent
0
CY2020Q4 cue Research And Development Contract Liability Noncurrent
ResearchAndDevelopmentContractLiabilityNoncurrent
1937575
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5121179
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2368787
CY2021Q4 us-gaap Liabilities
Liabilities
17908863
CY2020Q4 us-gaap Liabilities
Liabilities
20622328
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32202496
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32202496
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30351366
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30351366
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
32202
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
30351
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
262906084
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
232159029
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2203061
CY2020 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
17
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
78911472
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
83400935
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
99533800
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14941370
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3154325
CY2020 us-gaap Restricted Stock Award Forfeitures
RestrictedStockAwardForfeitures
271051
CY2020 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
17452
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17306678
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14651205
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41346765
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33545705
CY2021 us-gaap Operating Expenses
OperatingExpenses
58653443
CY2020 us-gaap Operating Expenses
OperatingExpenses
48196910
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-43712073
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
7131
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-197446214
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-153285039
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
65492072
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-45042585
CY2021 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
45898
CY2020 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
463914
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
45898
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
463914
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-43666175
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-44578671
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
495000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
206250
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-44161175
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-44784921
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-7131
CY2020 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
17452
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44168306
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-44767469
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.41
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.56
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31285418
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28688625
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
54583896
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
56682236
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10480782
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-44784921
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
78911472
CY2021 cue Issuance Of Common Stock From Atm Offering Net Of Sales Agent Commission And Fees Amount
IssuanceOfCommonStockFromAtmOfferingNetOfSalesAgentCommissionAndFeesAmount
17384668
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11515584
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2598782
CY2021 cue Issuance Of Common Stock Upon Net Exercise Of Warrants Shares
IssuanceOfCommonStockUponNetExerciseOfWarrantsShares
0
CY2021 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
55
CY2021 cue Restricted Stock Awards Withheld At Vesting To Cover Taxes Amount
RestrictedStockAwardsWithheldAtVestingToCoverTaxesAmount
-750183
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-7131
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-44161175
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
65492072
CY2021 us-gaap Profit Loss
ProfitLoss
-44161175
CY2020 us-gaap Profit Loss
ProfitLoss
-44784921
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1257662
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1057458
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
11515584
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
10480782
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
3035647
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
4202480
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-4581
CY2020 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
83694
CY2021 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
21550
CY2020 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0
CY2021 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0
CY2020 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
563232
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1725045
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
662584
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
50434
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
381132
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-250000
CY2020 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
4971
CY2021 cue Increase Decrease In Deposit Liabilities
IncreaseDecreaseInDepositLiabilities
-148515
CY2020 cue Increase Decrease In Deposit Liabilities
IncreaseDecreaseInDepositLiabilities
0
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
520398
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
741265
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1832752
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
559859
CY2021 cue Increase Decrease In Research And Development Contract Liability
IncreaseDecreaseInResearchAndDevelopmentContractLiability
-7973255
CY2020 cue Increase Decrease In Research And Development Contract Liability
IncreaseDecreaseInResearchAndDevelopmentContractLiability
503263
CY2021 cue Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
2906640
CY2020 cue Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
4678965
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38837166
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32494034
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
913039
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
595259
CY2021 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
21550
CY2020 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2021 cue Payments For Redemption Of Short Term Investments
PaymentsForRedemptionOfShortTermInvestments
-10000000
CY2020 cue Payments For Redemption Of Short Term Investments
PaymentsForRedemptionOfShortTermInvestments
-15000000
CY2021 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0
CY2020 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
9948867
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9108511
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4455874
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
17384668
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
56682236
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
55
CY2020 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
17
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2598782
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2203061
CY2021 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
750183
CY2020 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
271051
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19233322
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
58614263
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10495333
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
30576103
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
75016133
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
44440030
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
64520800
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
75016133
CY2021 cue Payments To Acquire Property Plant And Equipment In Account Payable Or Accrued Expenses
PaymentsToAcquirePropertyPlantAndEquipmentInAccountPayableOrAccruedExpenses
0
CY2020 cue Payments To Acquire Property Plant And Equipment In Account Payable Or Accrued Expenses
PaymentsToAcquirePropertyPlantAndEquipmentInAccountPayableOrAccruedExpenses
-446372
CY2021 cue Operating Lease Modification
OperatingLeaseModification
7616000
CY2021 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2014-12-31
CY2020 cue Operating Lease Modification
OperatingLeaseModification
5639000
CY2021Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
64400000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:5.187%;font-size:10.0pt;margin-top:10.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include estimates related to revenue, the accounting for potential liabilities and accrued expenses, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and the useful life with respect to long-lived assets and intangibles. Actual results could differ from those estimates.</span></p>
CY2021 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P15Y
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
495000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
206250
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6604472
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6122870
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
52509000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
72943275
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
10002550
CY2021Q4 cue Fair Value Assets Among Level2 And Level3 Transfers Amount
FairValueAssetsAmongLevel2AndLevel3TransfersAmount
0
CY2020Q4 cue Fair Value Assets Among Level2 And Level3 Transfers Amount
FairValueAssetsAmongLevel2AndLevel3TransfersAmount
0
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
9995419
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7131
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
10002550
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2021 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
7131
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
10002550
CY2020 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
17452
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5555822
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4914603
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3443873
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2806579
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2111949
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2108024
CY2021 cue Amortization Of Trademark
AmortizationOfTrademark
11666
CY2021 cue Amortization Of Capitalized License Expense
AmortizationOfCapitalizedLicenseExpense
336882
CY2020 cue Amortization Of Trademark
AmortizationOfTrademark
11666
CY2020 cue Amortization Of Capitalized License Expense
AmortizationOfCapitalizedLicenseExpense
265262
CY2021 us-gaap Depreciation
Depreciation
909114
CY2020 us-gaap Depreciation
Depreciation
780529
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
577390
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4619963
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2787211
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2006465
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1963983
CY2021Q4 cue Accrued Contract Manufacturing Services Current
AccruedContractManufacturingServicesCurrent
1273978
CY2020Q4 cue Accrued Contract Manufacturing Services Current
AccruedContractManufacturingServicesCurrent
108880
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
352114
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
326028
CY2021Q4 cue Accrued Contract Research Services Current
AccruedContractResearchServicesCurrent
987406
CY2020Q4 cue Accrued Contract Research Services Current
AccruedContractResearchServicesCurrent
388320
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0061
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0143
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0038
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0156
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.928
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.009
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.934
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.996
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4793253
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.10
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y7M20D
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
981800
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
17.31
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
454497
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
495000
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
10.14
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
16869399
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.86
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
289657
CY2020Q4 cue Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Options Exercisable Intrinsic Fair Value Per Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsExercisableIntrinsicFairValuePerShare
7.05
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
34539000
CY2021Q4 cue Deferred Tax Assets Tax Credit Carryforwards Research And Other
DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther
3708000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
52500
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
14.98
CY2021Q3 cue Share Based Compensation Arrangement By Share Based Payment Award Post Employment Options Exercise Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardPostEmploymentOptionsExercisePeriod
P90D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5030899
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.10
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y6M3D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1251000
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.88
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
382219
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.80
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
245512
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
14.42
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5654168
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.08
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y5M23D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3558987
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.31
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y9M21D
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
17521334
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
14442527
CY2021Q4 cue Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Options Exercisable Intrinsic Fair Value Per Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsExercisableIntrinsicFairValuePerShare
8.31
CY2021 cue Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Options Market Close Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsMarketClosePrice
11.31
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.31
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
94375
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
7.83
CY2020Q1 cue Share Based Compensation Arrangement By Share Based Payment Award Post Employment Options Exercise Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardPostEmploymentOptionsExercisePeriod
P12M
CY2020Q2 cue Share Based Compensation Arrangement By Share Based Payment Award Post Employment Options Exercise Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardPostEmploymentOptionsExercisePeriod
P36M
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11515584
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10480782
CY2021 cue Number Of Tranches
NumberOfTranches
2
CY2020Q4 cue Deferred Tax Assets Tax Credit Carryforwards Research And Other
DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther
2312000
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
-2000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
45994000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2021 cue Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1
CY2020 cue Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.06
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.07
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.29
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.30
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
861969
CY2021 cue Class Of Warrants Or Rights Cashless Issue Exercises
ClassOfWarrantsOrRightsCashlessIssueExercises
8048
CY2021 cue Class Of Warrant Or Right Number Of Securities Withheld
ClassOfWarrantOrRightNumberOfSecuritiesWithheld
1952
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
851969
CY2021Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
2500000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32202496
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32202496
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30351366
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30351366
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2773000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1976000
CY2021Q4 cue Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
2773000
CY2020Q4 cue Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
1974000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
363000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
341000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
7552000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
7446000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
301000000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
0
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
57555000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
44297000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
54782000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
42321000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.03
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.01
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.01
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.02
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0
CY2021 cue Effective Income Tax Rate Reconciliation Foreign Withholding Taxes
EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxes
0.01
CY2020 cue Effective Income Tax Rate Reconciliation Foreign Withholding Taxes
EffectiveIncomeTaxRateReconciliationForeignWithholdingTaxes
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.01
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.01
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1675000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1334000
CY2021 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
4963000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
30000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2068000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1675000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
4931675
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
4754796
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1004739
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
10691210
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
638358
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
10052853
CY2020 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
4593000

Files In Submission

Name View Source Status
0000950170-22-003969-index-headers.html Edgar Link pending
0000950170-22-003969-index.html Edgar Link pending
0000950170-22-003969.txt Edgar Link pending
0000950170-22-003969-xbrl.zip Edgar Link pending
cue-20211231.htm Edgar Link pending
cue-20211231.xsd Edgar Link pending
cue-20211231_cal.xml Edgar Link unprocessable
cue-20211231_def.xml Edgar Link unprocessable
cue-20211231_htm.xml Edgar Link completed
cue-20211231_lab.xml Edgar Link unprocessable
cue-20211231_pre.xml Edgar Link unprocessable
cue-ex10_28.htm Edgar Link pending
cue-ex10_34.htm Edgar Link pending
cue-ex21_1.htm Edgar Link pending
cue-ex23_1.htm Edgar Link pending
cue-ex31_1.htm Edgar Link pending
cue-ex31_2.htm Edgar Link pending
cue-ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img75202838_0.jpg Edgar Link pending
img75202838_1.jpg Edgar Link pending
img75202838_2.jpg Edgar Link pending
img75202838_3.jpg Edgar Link pending
img75202838_4.jpg Edgar Link pending
img75202838_5.jpg Edgar Link pending
img75202838_6.jpg Edgar Link pending
img75202838_7.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending